UK Indapamide Market to Reach $121.3 Million by 2035

UK indapamide market was valued at $81.3 million in 2025 and is projected to reach $121.3 million by 2035, growing at a CAGR of 4.2% during 2026 to 2035. The steady rise in hypertension prevalence and cardiovascular disease burden across the United Kingdom is significantly driving demand for thiazide-like diuretics such as indapamide. As a first-line or adjunct therapy for blood pressure management, indapamide plays a critical role in reducing stroke risk, heart failure incidence, and long-term cardiovascular complications.

Browse the full report description of “UK Indapamide Market Size, Share & Trends Analysis Report, By Product Type (Immediate-Release Indapamide, Sustained/Extended-Release Indapamide), By Dosage Strength (1.25 mg, 2.5 mg, Other Customized/Compounded Doses), By Application (Hypertension, Edema, Cardiovascular Risk Management), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/uk-indapamide-market

The market is experiencing stable growth due to increasing diagnosis rates, aging population demographics, and continued emphasis on preventive cardiovascular care. Immediate-release formulations remain widely prescribed due to cost efficiency and clinical familiarity, while sustained/extended-release variants are gaining traction for improved patient compliance and controlled pharmacokinetics. Hypertension continues to dominate application demand, supported by growing clinical guidelines recommending diuretics as part of combination therapy regimens.

In the United Kingdom, hypertension remains one of the most prevalent chronic conditions, significantly contributing to cardiovascular morbidity and mortality. According to the UK government’s Office for National Statistics (ONS), approximately 28% of adults in England were diagnosed with high blood pressure in 2023, with prevalence increasing sharply among individuals aged 65 and above. Additionally, NHS data indicates that cardiovascular diseases account for nearly 27% of all deaths annually, reinforcing the urgent need for effective blood pressure management strategies.

The increasing burden of hypertension has directly translated into higher prescription volumes for antihypertensive medications, including indapamide. As a cost-effective and clinically established diuretic, indapamide is widely used in both monotherapy and combination treatments, particularly for patients requiring long-term blood pressure control. The growing emphasis on early diagnosis and treatment is further supporting consistent demand across primary care and outpatient settings.

The UK government and National Health Service (NHS) have implemented several initiatives aimed at improving cardiovascular health outcomes, which are indirectly boosting the indapamide market. In May 2023, the NHS expanded its

Furthermore, the . These efforts include wider adoption of standardized treatment pathways and increased use of cost-effective medications such as indapamide. In addition, the UK government’s Major Conditions Strategy (2023–2025) emphasizes integrated care models and improved access to essential cardiovascular medicines. This policy framework is encouraging healthcare providers to adopt evidence-based pharmacological treatments, including diuretics, to manage high-risk patient populations more effectively.

Key players operating in the UK indapamide market include Servier Laboratories Ltd, Teva UK Limited, Accord Healthcare Limited, Viatris (Mylan/Viatris UK Healthcare), and Zentiva Pharma UK Ltd, among others. These companies are focusing on strengthening their generic drug portfolios, optimizing supply chains, and enhancing product accessibility to maintain competitive positioning in the market.

• In April 2024, Zentiva joined the EU’s Critical Medicines Alliance, focusing on improving supply chain resilience and ensuring consistent availability of essential generic medicines. The company’s active participation in vulnerability assessments and policy discussions highlights its commitment to addressing medicine shortages and enhancing manufacturing capabilities across the UK.

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
• By Product Type
• By Dosage Strength
• By Application
• Competitive Landscape – Servier Laboratories Ltd, Teva UK Limited, Accord Healthcare Limited, Viatris (Mylan/Viatris UK Healthcare), and Zentiva Pharma UK Ltd, among others.

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• Who are the leading players in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Indapamide Market Segment

By Product Type

• Immediate-Release Indapamide
• Sustained/Extended-Release Indapamide

By Dosage Strength

• 25 mg
• 5 mg
• Other Customized/Compounded Doses

By Application

• Hypertension
• Edema
• Cardiovascular Risk Management

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-indapamide-market